Last reviewed · How we verify
NCT04181749: P-VECT
Peri-vascular Adipose Tissue Inflammation Evaluated Using Coronary CT Angiography
Phase 2 trial testing aspirin and atorvastatin in Cardiovascular Risk Factor in 200 participants. Status unknown.
31 January 2024
Quick facts
| Lead sponsor | University of Leicester |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 200 |
| Start date | 18 November 2020 |
| Primary completion | 31 January 2024 |
| Estimated completion | 31 January 2024 |
| Sites | 3 locations across United Kingdom |
Drugs / interventions tested
- aspirin and atorvastatin — full drug profile →
Conditions studied
- Cardiovascular Risk Factor — all drugs for Cardiovascular Risk Factor →
Sponsor
University of Leicester
Who can join
Adults 30 to 80, any sex, with Cardiovascular Risk Factor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The P-VECT Study proposes to test the use of CCTA-derived FAI measurements in a group of patients with coronary artery inflammation, who will receive routinely-used statin and aspirin treatment. The P-VECT Study is a pilot study that will provide the rationale and data for power calculations to enable design of pivotal trials of the clinical effectiveness of FAI.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04181749
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiovascular Risk Factor
Currently open trials in the same condition.
- NCT07268781 — Impact of Golden Rice-Piper Crocatum Cookies on Lipid Control in Diabetes Mellitus Patients · NA · active not recruiting
- NCT06225544 — Lumasiran in Hyperoxalaemic Patients on Haemodialysis · Phase 2 · recruiting
- NCT06372054 — TORNADO-Omics Techniques and Neural Networks for the Development of Predictive Risk Models · recruiting
- NCT05887622 — The Potassium Supplementation Study · NA · recruiting
- NCT04962061 — A Combined Multidomain Intervention to Prevent Cognitive Decline Associated With Cardiovascular Risk Factors. · NA · recruiting
Other University of Leicester trials
Trials by the same sponsor.
- NCT07389785 — Age Related Chromatin Remodelling as a Therapeutic Target for Organ Protection in Cardiac Surgery · active not recruiting
- NCT07014579 — Using Heart Electrical Signals to Study How Well Treatments Prevent Dangerous Heart Rhythms in Active People · not yet recruiting
- NCT06955663 — Exercise Support and Rehabilitation for Patients After Spontaneous Coronary Artery Dissection · NA · recruiting
- NCT06629675 — Make Every Step Count: Personalised Music Feedback to Walking for People Living With COPD · NA · recruiting
- NCT06844656 — Understanding the Increased Risk of Atrial Fibrillation in Athletes: a Case-control Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04181749 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Leicester
- Last refreshed: 19 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04181749.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing